Medicare Enrolled

Dr. Lara Paraskos, MD

Endocrinology · South Miami, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
6141 SUNSET DR STE 403, South Miami, FL 33143
3056652300
In practice since 2008 (17 years)
NPI: 1912171075 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Paraskos from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Paraskos? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Paraskos

Dr. Lara Paraskos is an endocrinology in South Miami, FL, with 17 years in practice. Based on federal Medicare data, Dr. Paraskos performed 20,278 Medicare services across 2,168 unique beneficiaries.

Between the years covered by Open Payments, Dr. Paraskos received a total of $48,973 from 81 pharmaceutical and/or device companies across 1320 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Paraskos is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 4% volume in FL$ $48,973 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,278
Medicare services
Top 4% in FL for endocrinology
2,168
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,193 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)17,520$19$46
Office visit, established patient (30-39 min)784$97$345
Office visit, established patient (20-29 min)362$73$235
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle293$58$240
Office visit, established patient, complex (40-54 min)285$141$468
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report263$28$150
Blood draw (venipuncture)239$8$9
Ultrasound scan of head and neck soft tissue167$88$369
Blood glucose (sugar) test performed by hand-held instrument141$3$10
New patient office visit (45-59 min)81$116$541
New patient office visit, complex (60-74 min)60$157$680
Fine needle aspiration biopsy using ultrasound guidance, first growth32$113$750
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin26$45$200
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less25$50$222
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.1% high complexity
88.8% medium
11.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$48,973
Total received (2018-2024)
Avg $6,996/year across 7 years
Top 11% in FL for endocrinology
81
Companies
1,320
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$22,665 (46.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,454 (43.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,854 (9.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,626
2023
$4,772
2022
$8,457
2021
$15,350
2020
$10,561
2019
$3,418
2018
$2,789

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$24,077
IBSA Pharma Inc.
$4,419
Lilly USA, LLC
$2,674
Xeris Pharmaceuticals, Inc.
$1,434
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,377
AstraZeneca Pharmaceuticals LP
$1,250
SANOFI-AVENTIS U.S. LLC
$1,110
Insulet Corporation
$919
Abbott Laboratories
$907
Radius Health, Inc.
$792
Tandem Diabetes Care, Inc.
$689
Amgen Inc.
$668
Mannkind Corporation
$609
MannKind Corporation
$590
Amneal Pharmaceuticals LLC
$491
Shire North American Group Inc
$491
ABBVIE INC.
$411
RECORDATI_RARE_DISEASES_INC.
$347
Antares Pharma, Inc.
$339
Merck Sharp & Dohme Corporation
$328
AbbVie, Inc.
$321
Bayer Healthcare Pharmaceuticals Inc.
$284
AbbVie Inc.
$248
Corcept Therapeutics
$221
Amarin Pharma Inc.
$199
PFIZER INC.
$196
Embecta Corp.
$192
Medtronic, Inc.
$191
Dexcom, Inc.
$181
Alexion Pharmaceuticals, Inc.
$173
Aytu BioScience, Inc
$154
Bayer HealthCare Pharmaceuticals Inc.
$154
Janssen Pharmaceuticals, Inc
$136
CeQur Corporation
$129
Alvogen Inc
$118
Currax Pharmaceuticals LLC
$115
Horizon Therapeutics plc
$110
VIVUS, Inc.
$101
Ipsen Biopharmaceuticals, Inc
$98
VIVUS LLC
$96
Zealand Pharma US, Inc.
$95
BETA BIONICS, INC.
$93
Ultragenyx Pharmaceutical Inc.
$87
Supernus Pharmaceuticals, Inc.
$87
LifeScan, Inc.
$82
Becton, Dickinson and Company
$72
Kyowa Kirin, Inc.
$68
Clarus Therapeutics Inc.
$63
Azurity Pharmaceuticals, Inc.
$59
Roche Diabetes Care, Inc.
$59
Alfasigma USA, Inc.
$56
Eisai Inc.
$55
Gemini Laboratories, LLC
$54
Acella Pharmaceuticals, LLC
$48
Senseonics, Incorporated
$46
Medtronic MiniMed, Inc.
$43
Amryt Pharma Holdings Ltd
$40
Valeritas, Inc.
$37
Tolmar, Inc.
$35
Amphastar Pharmaceuticals, Inc.
$35
Acerus Pharmaceuticals Corporation
$31
Orexigen Therapeutics, Inc.
$28
VistaPharm, Inc.
$27
GRT US Holding, Inc.
$25
EUSA Pharma (US) LLC
$24
GENZYME CORPORATION
$24
SANOFI PASTEUR INC.
$22
Chiesi USA, Inc.
$22
Verity Pharmaceuticals Inc.
$21
Kowa Pharmaceuticals America, Inc.
$20
Ferring Pharmaceuticals Inc.
$19
Astellas Pharma US Inc
$18
Ascensia Diabetes Care Us Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$17
ASCEND Therapeutics US, LLC
$17
Nalpropion Pharmaceuticals LLC
$16
Intuity Medical Inc
$16
Gilead Sciences, Inc.
$16
Strongbridge US INC.
$16
Nalpropion Pharmaceuticals, Inc.
$16
KVK-Tech, Inc.
$3
Top 3 companies account for 63.6% of total payments
Associated products mentioned in payments ›
AFREZZA · Accu-Chek Guide Me · Adthyza · Androgel · BAQSIMI · BD NANO · BD Nano 2nd Gen Pen Needle · BINOSTO · BYDUREON · Belviq · CONTRAVE · Cables · CeQur Simplicity · Creon · Crysvita · DC ACCU-CHEK Diabetes Management Solutions · Dexcom CGM · Dexcom G6 Transmitter · EVENITY · Eversense · FARXIGA · FORTEO · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · HUMALOG · HUMULIN · HUMULIN R 500 · INPEN SMART INSULIN DELIVERY SYSTEM · INVOKANA · ISTURISA · InPen · JANUVIA · JARDIANCE · JATENZO · Kerendia · Kits and Accessories · Korlym · LICART · LOKELMA · Lenvima · Livalo · MACRILEN · MINIMED 770G · MINIMED 780G · MOUNJARO · MYCAPSSA · MYCARELINK · Minimed 670G System · Minimed Paradigm Revel · NATPARA · NATPARA (PARATHYROID HORMONE) · NOCDURNA · NP Thyroid 60 · Natesto · OT Verio Reflect "One Touch Meter and Strips" · OTREXUP · Omnipod · OneTouch · Ozempic · PANCREAZE · Pogo Automatic Blood Glucose Monitoring System · Prolia · QSYMIA · Qsymia · Qutenza · RECORLEV · RYBELSUS · Repatha · Rybelsus · SIGNIFOR LAR · SOLIQUA · SOLIQUA 100/33 · SOMATULINE DEPOT · SOMAVERT · STEGLATRO · STEGLUJAN · STRENSIQ · SYNJARDY · SYNTHROID · Saxenda · Software · Somatuline Depot · Strensiq · Sylvant · Synthroid · TEPEZZA · TERIPARATIDE · THYROGEN · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Thyquidity · Tirosint · Tlando · Tresiba · Tymlos · UNITHROID · V-GO · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XIGDUO · XYOSTED · ZEGALOGUE · ZOMACTON · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (46%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $242 per 100 Medicare services performed
Looking for a endocrinology in South Miami?
Compare endocrinologys in the South Miami area by procedure volume, costs, and industry payment transparency.
Browse endocrinologys nearby

Geographic Context

Endocrinologys within 10 mi
106
Per 100K population
3.9
County median income
$68,694
Nearest hospital
SOUTH MIAMI HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Paraskos is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), and high industry engagement (speaking/promotional, top 11%), with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Paraskos experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Paraskos performed 17,520 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Paraskos receive payments from pharmaceutical companies?
Yes. Dr. Paraskos received a total of $48,973 from 81 companies across 1,320 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Paraskos's costs compare to other endocrinologys in South Miami?
Dr. Paraskos's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Paraskos) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →